CI

At a glance

ClinicalIndex Comparison Record
Phase 2Terminated· 4 enrolled
Drug / intervention
Hydroxychloroquine +2 moredrug
Likely dose
Hydroxychloroquine 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04381988
NCT04381988Phase 2Terminated
Terminated
CompareCT.gov

A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)

Memorial Sloan Kettering Cancer Center·interventional·Posted May 11, 2020·Updated Oct 27, 2021

In Brief

A Phase 2 clinical trial evaluating Hydroxychloroquine, Placebo, and 1 other intervention for COVID-19 and Cancer. Terminated early, enrolled 4 participants across 7 sites.

Signals

Trial was terminated early

Detailed Summary

The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study drug and is taken in the same way, but it does not contain any active ingredients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2TerminatedFinished
202120222023202420252026
First PostedMay 11, 2020
Enrollment StartMay 7, 2020
Primary CompletionApr 21, 2021
TodayJul 1, 2026
Enrollment to primary: 11 monthsPosted 6.1 years ago

Interventions

Hydroxychloroquinedrug

400mg daily

Placeboother

400mg daily

Radiation therapyradiation

Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.